Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD) |
NCT00606632: Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody |
|
|
| Completed | 3 | 226 | US | 124-Iodine-cG250 (124I-cG250), Ca9-SCAN, CT | Heidelberg Pharma AG | Renal Cell Carcinoma, Kidney Cancer | 11/09 | 12/09 | | |
NCT00087022 / 2004-000353-38: Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer |
|
|
| Completed | 3 | 864 | Canada, US, RoW | girentuximab, Rencarex®, cG250 and WX-G250, placebo | Heidelberg Pharma AG | Kidney Cancer | 10/12 | 10/12 | | |
| Withdrawn | 3 | 0 | US | Iodine (124I) Girentuximab, 124I-cG250 | Heidelberg Pharma AG | Renal Cell Carcinoma, Kidney Cancer | 12/18 | 12/19 | | |
NCT02883153: Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma |
|
|
| Completed | 2/3 | 30 | Europe | Zirconium-89 girentuximab PET/CT, girentuximab | Radboud University Medical Center | Renal Cell Carcinoma | 06/17 | 06/17 | | |